's-Gravenhage

• The efficacy of the addition of TRAstuzumab and Pertuzumab to neoadjuvant chemoradiation: a randomized multi-center study in resectable HER2 … Recruiting
  2024-513797-22-00 5 2022-03-09 HER2 positive esophageal adenocarcinoma
• Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma … Recruiting
  2023-508922-83-00 10 2021-03-17 Advanced Non-Small Cell Lung Cancer
• Study of two doses of crizanlizumab versus placebo in adolescent and adult sickle cell disease patients Recruiting
  2023-508689-14-00 5 2019-09-16 Sickle cell disease
• Evaluating, clinical and immunological effects of rituximab with cyclophosphamide compared to rituximab alone in AAV patients Recruiting
  2023-507868-39-00 6 2019-05-03 ANCA Vasculitis
• A randomized trial to investigate the reset of humoral autoimmunity by combining belimumab with rituximab in severe systemic lupus erythemat … Recruiting
  2023-507867-20-00 10 2018-10-04 Lupus Erythematosus, Systemic
• Prospective Randomized Open-label Trial to Evaluate risk faCTor management in patients with Unruptured intracranial aneurysms (PROTECT-U) Recruiting
  2024-517236-22-00 5 2017-09-20 Intradural saccular unruptured aneurysm
• Neoadjuvant immune checkpoint inhibition and novel IO combinations in early-stage colon cancer - the NICHE trial Recruiting
  2024-513314-35-00 4 2017-01-20 Adenocarcinoma of the Colon or rectosigmoid (considered as non-rectal)
• DRUP trial Recruiting
  2023-509152-33-00 4 2016-07-25 Advanced solid tumor
• POEM Study Ended recruitment
  2024-519386-21-01 5 2025-01-29 Gestational diabetes mellitus
• Prevention of the return of nephrotic syndrom in children by adding levamisole to prednisolone treatment Ended recruitment
  2024-517467-23-00 5 2024-11-29 steroid sensitive idiopathic nephrotic syndrome
• A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC Ended recruitment
  2023-504753-12-00 5 2024-10-01 Lung Cancer, Non-Small Cell
• Comparing the effectiveness of our tailor-made management approach with routine care from a clinical, patient's as well as an economic point … Ended recruitment
  2024-511530-12-01 6 2024-10-01 Rheumatoid arthritis according to 2010 criteria
• First line treatment with VeNEtoclaX and ibruTinib induction followed by obinutuzumab intenSificaTion Exclusively in CLL/SLL Patients not in … Ended recruitment
  2022-502808-72-00 4 2024-09-11 Chronic Lymphocytic Leukemia
• MAD Ended recruitment
  2024-516379-34-00 6 2024-08-02 Myopia
• ARTEMIS - A research study to look at how ziltivekimab works compared to placebo in people who have had a heart attack Ended recruitment
  2023-506876-28-00 5 2024-08-01 The medical condition we are investigating is type 1 AMI (STEMI and NS
• Comparison of targeted radiotherapy with and without short-term hormonal treatment (6 months) Ended recruitment
  2024-511252-41-00 5 2024-07-30 Patients with biochemical recurrence after primary treatment of prosta
• DUTCH-WAIST Ended recruitment
  2022-501392-81-00 6 2024-07-25 Obesity
• A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu … Ended recruitment
  2022-502781-24-01 5 2024-06-05 ASCVD - Atherosclerotic Cardiovascular Disease
• Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change i … Ended recruitment
  2023-506906-38-00 5 2024-05-23 Follicular Lymphoma
• A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab i … Ended recruitment
  2023-506948-17-00 5 2024-04-05 Previously Untreated Chronic Lymphocytic Leukemia
• A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal- … Ended recruitment
  2022-502446-27-00 5 2024-02-26 Relapsed or Refractory Myeloma
• Phase 3 study of belzutifan plus pembrolizumab as adjuvant treatment in renal cell carcinoma (RCC) Ended recruitment
  2023-505023-31-00 5 2023-11-17 Renal cell carcinoma
• A study to compare the study treatment darolutamide in combination with androgen deprivation therapy (ADT) to placebo in combination with AD … Ended recruitment
  2022-501343-33-00 5 2023-10-18 Biochemically recurrent prostate cancer
• Safe, effective and cost-effective oxygen saturation targets for children and adolescents with respiratory distress: a randomized controlled … Ended recruitment
  2023-504817-56-00 6 2023-09-05 Bronchiolitis

Showing 73–96 of 149 trials